Clinical Trials Logo

Filter by:
NCT ID: NCT05709977 Completed - Allergic Rhinitis Clinical Trials

Acupuncture for Nasal Congestion in Allergic Rhinitis

ANCAR
Start date: April 20, 2023
Phase: N/A
Study type: Interventional

Allergic rhinitis (AR) is a disorder that affects more than 500 million people worldwide. Nasal congestion is one of the most general and bothersome symptoms in rhinitis, which affects the quality of life (QOL). Current medications are undesirable due to their side-effects. Acupuncture for AR in general can be considered as safe and can be seen as a potential therapeutic intervention for nasal congestion. Evidence supported that acupuncture is clinically used for signs and symptoms of nose disorders, such as nasal congestion, with effectiveness, but whether acupuncture has immediate, post-treatment and long-term effects on nasal congestion in AR is not verified by strictly designed clinical study. The ANCAR trial uses a standard treatment protocol with a fixed set of acupuncture points - to be as scientific as possible from Western medical viewpoint - to open the nose and affect underlying energetic imbalance and immunity at the same time, to maintain its nose opening effect. This novel acupuncture treatment protocol can be seen as a solid and profound approach from which every AR patient may benefit.

NCT ID: NCT05707403 Completed - Healthy Clinical Trials

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Start date: February 14, 2023
Phase: Phase 1
Study type: Interventional

This trial is intended to examine the absolute oral bioavailability of BI 1015550 as tablet formulation for oral administration, using an intravenous microtracer approach with [14C]-labelled BI 1015550. These data are considered necessary to further support the understanding of the pharmacokinetics of BI 1015550.

NCT ID: NCT05706350 Completed - Immune Response Clinical Trials

Plant Stanol Esters and Influenza Vaccination

Start date: October 11, 2022
Phase: N/A
Study type: Interventional

Plant stanols are known to lower low-density lipoprotein cholesterol (LDL-C). However, recent studies have suggested that these compounds also beneficially influence the immune system, e.g. increasing vaccine-specific antibody titers. BMI and age have previously been negatively associated to vaccination responses. If plant stanols indeed have beneficial effects on the immune system, people with overweight or obesity and higher age might benefit from consuming plant stanols prior to receiving the influenza vaccination.

NCT ID: NCT05703087 Completed - Clinical trials for Osteoarthritis, Knee

Positive Cueing in Knee Arthroplasty.

Start date: September 21, 2021
Phase: N/A
Study type: Interventional

To the knowledge of the investigators, the feasibility of an RCT assessing the use of positive cueing in an information video for patients undergoing primary TKA is currently unclear. The investigators conducted a feasibility study with the primary objective to assess the acceptability of the randomized controlled trial (RCT) procedure for participating patients. The secondary objective was to evaluate the rate of recruitment, the comprehensibility (do patients understand what is expected of them during the trial) and if there were any adjustments necessary to the design of the study. The outcome of the current feasibility study will be used to determine whether adjustments are required to the design of the RCT before we proceed.

NCT ID: NCT05702177 Completed - Healthy Clinical Trials

A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

Start date: January 5, 2023
Phase: Phase 1
Study type: Interventional

A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

NCT ID: NCT05698121 Completed - Cardiac Disease Clinical Trials

Evaluation of a Preparatory eHealth Intervention to Support Cardiac Patients During Their Waiting Period.

PReCARE
Start date: February 8, 2023
Phase: N/A
Study type: Interventional

The goal of this pilot study is to evaluate the feasibility of an eHealth intervention for cardiac patients during their waiting period before their rehabilitation. The main questions it aims to answer are: - What is the feasibility of an eHealth intervention designed for cardiac patients with a low socio-economic position during the waiting period before their cardiac rehabilitation. - What is the potential effect of this intervention on patient activation and feelings of certainty and guidance. Participants will: - Be randomised in either intervention or control group - Fill in a questionnaire at the start of their waiting period (after release from the hospital) - Use the eHealth intervention during their waiting period (usually 2 to 6 weeks)(intervention group only) - Fill in a questionnaire at the start of their rehabilitation Researchers will compare intervention and control group to see if the intervention has improved patient activation and feelings of certainty and guidance.

NCT ID: NCT05690373 Completed - Vaccine Response Clinical Trials

Probiotics and Influenza Vaccination Response

VERB
Start date: March 20, 2023
Phase: N/A
Study type: Interventional

Assess efficacy of oral ingestion of a probiotic product on immune function in a population of healthy adult men and women in a clinical vaccination study.

NCT ID: NCT05687916 Completed - Narcolepsy Type 2 Clinical Trials

A Study of TAK-861 in Participants With Narcolepsy Type 2

Start date: January 9, 2023
Phase: Phase 2
Study type: Interventional

The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of Wakefulness Test (MWT). The study will enroll approximately 60 participants and they will be randomly assigned to 3 groups (20 per group) to take one of two different doses of TAK-861 or a placebo. All the participants will receive the treatment for 8 weeks. Participants will be asked to complete some questionnaires during the study. This trial will be conducted in North America, Europe, and Asia Pacific.

NCT ID: NCT05687903 Completed - Narcolepsy Type 1 Clinical Trials

A Study of TAK-861 in Participants With Narcolepsy Type 1

Start date: January 9, 2023
Phase: Phase 2
Study type: Interventional

The main aim of this study is to see how TAK-861 works on symptoms of narcolepsy, including excessive daytime sleepiness and cataplexy. Approximately 100 participants will take part in the study across North America, Europe and Asia Pacific. The treatment (TAK-861 or placebo) will be administered for 8 or 12 weeks. After this treatment period the participant will have the option to participate in a separate, long- term extension study during which all participants will be treated with TAK-861.

NCT ID: NCT05682456 Completed - Clinical trials for Cardiovascular Diseases

High-fat Challenge Induced Trained Innate Immunity (SHAKE Study)

Start date: May 6, 2019
Phase: N/A
Study type: Interventional

The goal of this randomized controlled cross-over trial is to investigate whether a single high-fat challenge can induce trained innate immunity in healthy volunteers. The main question it aims to answer is: Can a single high-fat challenge induce a persistent pro-inflammatory and pro-atherogenic monocyte phenotype, as detected by an augmented cytokine production capacity? To study this, participants will receive an oral high-fat and reference shake in a cross-over design and blood will be drawn before and at 1, 2, 4, 6, 24, and 72 hours after the shakes.